<DOC>
	<DOC>NCT01623544</DOC>
	<brief_summary>The objective of this study is to compare the real-world effectiveness of BFC and FSC in asthma patients new to ICS/LABA combination therapy in a population of U.S. health plan enrollees.</brief_summary>
	<brief_title>Asthma Comparative Effectiveness Study</brief_title>
	<detailed_description>A U.S. retrospective database analysis evaluating the comparative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol among asthma patients</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<criteria>Continuous health plan enrollment for 12 months before and after index Rx At least two prescription fills for BFC or FSC within 12 months Asthma claims diagnosis, and 12 to 64 years of age at the time of first prescription Evidence of COPD Claims diagnosis of any of inflammatory diseases or cancer Presence of Rx for more than one type of ICS/LABA combination on index date Chronic steroid use or Xolair use prior to ICS/LABA index treatment</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Comparative Effectiveness</keyword>
	<keyword>Symbicort</keyword>
</DOC>